Business Description
Founded in 2019 and headquartered in Nedlands, Australia, Argenica Therapeutics is working to develop medicines that protect brain cells from damage. The company's primary focus is ARG-007, a drug currently in Phase 2 clinical trials aimed at limiting the loss of brain tissue following stroke and similar injuries.
